

Curriculum Vitae

Name: Jinhong Chen, MD., PhD.

Current affiliation: Chief Surgeon, Professor, Doctoral Supervisor, Division of Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University

Mailing address (office): 12 Middle Wulumuqi Road

City/ZIP: Shanghai, 200040

Country: China

Phone (office): +86-21-5288-7175

E-mail: jinhongch@hotmail.com

Fields of Expertise:

Laparoscopic hepatobiliary surgery for benign or malignant liver disease (laparoscopic liver resection, anatomic or non-anatomic; laparoscopic living donor liver Sectionectomy), over 200 cases per year;

Open hepatobiliary surgery for benign or malignant liver disease (hemihepatectomy, extended hemihepatectomy, complex hilar cholangiocarcinoma resection);

Laparoscopic and open colorectal cancer resection.

Honors & Titles

Global Clinical Research Scholar (GCSRT) of Harvard University;

Founding member of the World Laparoscopy and Liver Society;

Deputy chief of the Liver Surgery Branch, Shanghai Medical Association;

Member of the Youth Committee of the Surgery Branch, Chinese Medical Association;

National Natural Science Fund evaluation expert;

Chinese Medical Science and Technology Award evaluation expert;

Shanghai Outstanding Young Medical Talent, etc.

Research Grants

"The role of osteopontin in the formation of gallstones and its clinical application", National Natural Science Foundation of China (Grant No. 30801105

, 2009.1-2011.12), PI;

"The mechanism of osteopontin intervention cholesterol metabolism and the formation of cholesterol stones in the gallbladder", National Natural Science Foundation of China (Grant

No. 81270536, 2013.1-2016.12), PI;

"New strategies for precise diagnosis and treatment of hepatitis B-related hepatocellular carcinoma metastasis after surgery", National Science and Technology Major Project of the

Ministry of Science and Technology of China (Grant No. 2017ZX10203207, 2017.1-2021.6),

PI;

“The mechanism of GOLM1 mediating the interaction of osteopontin and cholesterol to promote the formation of cholesterol gallstones in the gallbladder”, National Natural Science Foundation of China (2021.1-2024.12), PI.

Recent Publications:

1. Zheng Y, Huang C, Lu L, et al: STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. *J Hematol Oncol* 14:16, 2021
2. Su X, Zhao L, Shi Y, et al: Clonal evolution in liver cancer at single-cell and single-variant resolution. *J Hematol Oncol* 14:22, 2021
3. Lu L, Wang ZX, Zhu WW, et al: Left Hepatic Vein Preferential Approach Based on Anatomy Is Safe and Feasible for Laparoscopic Living Donor Left Lateral Sectionectomy. *Liver Transpl* 27:88-95, 2021
4. Yang LY, Luo Q, Lu L, et al: Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. *J Hematol Oncol* 13:3, 2020
5. Yang L, Liu L, Zhang R, et al: IL-8 mediates a positive loop connecting increased neutrophil extracellular traps (NETs) and colorectal cancer liver metastasis. *J Cancer* 11:4384-4396, 2020
6. Shao W, Zhu W, Lin J, et al: Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR. *Neoplasia* 22:1-9, 2020
7. Shao J, Xu Y, Li H, et al: LMCD1 antisense RNA 1 (LMCD1-AS1) potentiates thyroid cancer cell growth and stemness via a positive feedback loop of LMCD1-AS1/miR-1287-5p/GLI2. *Ann Transl Med* 8:1508, 2020
8. Lu M, Zhu WW, Wang X, et al: ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition. *Cell Metab* 29:886-900.e5, 2019